NCT04074746 2025-09-30
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
M.D. Anderson Cancer Center
Phase 1/2 Completed
Clinical Trials
5 trialsNCT04101331 2024-11-05
REDIRECT
Affimed GmbH
Phase 2 Completed
NCT03192202 2023-07-20
AFM13 in Relapsed/Refractory Cutaneous Lymphomas
Columbia University
Phase 1/2 Completed
NCT02321592 2020-11-13
GHSG-AFM13
University of Cologne
Phase 2 Completed
NCT02665650 2019-05-16
Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Affimed GmbH
Phase 1 Completed